Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Short term Debt (2022 - 2023)

bioAffinity Technologies (BIAF) has disclosed Short term Debt for 2 consecutive years, with $42334.0 as the latest value for Q2 2023.

  • Quarterly Short term Debt changed N/A to $42334.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $42334.0 through Jun 2023, changed N/A year-over-year, with the annual reading at $251746.0 for FY2022, N/A changed from the prior year.
  • Short term Debt for Q2 2023 was $42334.0 at bioAffinity Technologies, down from $168430.0 in the prior quarter.
  • The five-year high for Short term Debt was $500000.0 in Q3 2022, with the low at $42334.0 in Q2 2023.